Quick Summary:
- Eli Lilly (LLY, Financial) shares surged by 14% following successful trial results for its new diabetes drug.
- Analysts predict an average price target of $1,014.97, indicating a significant upside potential.
- The stock holds an "Outperform" rating with an estimated GF Value of $1,126.68.
Eli Lilly (LLY), the prominent Indiana-based pharmaceutical company, witnessed an exhilarating climb in its stock value, surging approximately 14% in premarket trading. This impressive boost comes on the heels of remarkable Phase 3 trial results for its oral GLP-1 receptor agonist, orforglipron, targeting type 2 diabetes. Eli Lilly's breakthrough demonstrated substantial weight loss and A1C reduction, setting a new benchmark in the competitive obesity drug market.
Wall Street Analysts Projection
In a detailed analysis by 25 experts, Eli Lilly and Co (LLY, Financial) is projected to reach an average price target of $1,014.97 within one year. The high estimate stands at $1,190.00, while the low is $800.00, pointing to an impressive 38.11% upside from its current valuation of $734.90. Investors looking for further insights can explore more on the Eli Lilly and Co (LLY) Forecast page.
The collective assessment from 29 brokerage firms places Eli Lilly and Co (LLY, Financial) with an average recommendation score of 1.9, reflecting an "Outperform" stance. This rating is based on a scale from 1 (Strong Buy) to 5 (Sell), making Eli Lilly a compelling option for investors.
According to GuruFocus estimates, the projected GF Value for Eli Lilly and Co (LLY, Financial) in the next year is $1,126.68, suggesting a robust 53.31% upside potential from its present price of $734.9. The GF Value is GuruFocus' assessment of what the fair price should be, grounded in the stock’s historical trading multiples, past business growth trajectories, and future performance predictions. Dive deeper into these metrics on the Eli Lilly and Co (LLY) Summary page.
